Elanco Animal Health Incorporated (ELAN) Earnings Call Transcripts
Elanco Animal Health Incorporated's Latest Earnings Call - June 2, 2026
In the Q1 2026 earnings call, Elanco Animal Health reported strong performance, marking its best quarter since the IPO in 2018. Revenue reached $1.2 billion, exceeding expectations, and the company raised its full-year guidance for organic revenue growth to 5-7%. Management highlighted a robust pipeline with 15 candidates and 5-6 potential blockbusters, signaling confidence in sustained growth driven by innovation in both pet and farm segments.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $1.2B (beat) |
| Organic Revenue Growth Guidance | 5-7% (positive) |
| Adjusted EBITDA Growth | high single digits (inline) |
| Adjusted EPS Growth | low double digits (inline) |
| Free Cash Flow | over $1B (positive) |
| Leverage Ratio | under 3x (positive) |
Guidance from management
Elanco expects organic revenue growth of 5-7% for the full year 2026, with adjusted EBITDA growth in the high single digits and adjusted EPS growth in the low double digits. The company is also targeting free cash flow of over $1 billion over the next three years.
What analysts pressed on
Analysts expressed concerns about potential pricing pressures and the sustainability of growth in the pet health market amid macroeconomic uncertainties. There were questions regarding how Elanco plans to maintain its competitive edge and market share in a rapidly evolving industry landscape.
Main topics on the call
- Revenue Growth Acceleration — Elanco reported Q1 revenue of $1.2 billion, marking a significant increase and the best quarter since its IPO. Management stated, "we're now projecting 5% to 7% for the rest of this year," indicating a strong outlook for...
- Innovation Pipeline — The company has a pipeline of 15 candidates and expects to launch 5-6 new blockbuster products by 2031. CEO Jeff Simmons noted, "we're committing to another 5 to 6 in the next 5 years," showcasing a strong focus on innov...
- U.S. Pet Health Market Dynamics — Bobby Modi emphasized the resilience of the U.S. pet health market, stating, "the U.S. pet health market grew 5% in 2025," and projected continued growth despite macroeconomic challenges. The company expects high single-...
- Cash Flow and Leverage Improvement — Elanco is on track to generate over $1 billion in free cash flow over the next three years and aims to reduce its leverage ratio to below 3x by 2027. Management stated, "we've delevered 2 full turns in the last 2 years,"...
Read the full Elanco Animal Health Incorporated transcript (June 2, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Elanco Animal Health Incorporated
Elanco Animal Health Incorporated (ELAN) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on NYSE and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 90 calls on record spanning January 10, 2020 to November 6, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 90 Elanco Animal Health Incorporated earnings call transcripts on record, spanning January 10, 2020 to November 6, 2026. Based on this history, Elanco Animal Health Incorporated reports quarterly. The most recent call on file is dated November 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- ELAN
- Exchange
- NYSE
- Country
- US
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 90
- First call
- January 10, 2020
- Most recent
- November 6, 2026
- Reporting cadence
- quarterly